|
1
|
Zhang Y: Epidemiology of esophageal
cancer. World J Gastroenterol. 19:5598–5606. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Roshandel G, Majdzadeh R, Keshtkar A,
Aramesh K, Sedaghat SM and Semnani S: Healthcare utilization in
patients with esophageal cancer in a high risk area in northeast of
Iran. Asian Pac J Cancer Prev. 12:2437–2442. 2011.PubMed/NCBI
|
|
3
|
Maleki I, Shekarriz R, Nosrati A and Orang
E: Simultaneous esophageal squamous cell carcinoma and
adenocarcinoma: A case report. Middle East J Dig Dis. 7:257–260.
2015.PubMed/NCBI
|
|
4
|
Roshandel G, Boreiri M, Sadjadi A and
Malekzadeh R: A diversity of cancer incidence and mortality in West
Asian populations. Ann Glob Health. 80:346–357. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lu CL, Lang HC, Luo JC, Liu CC, Lin HC,
Chang FY and Lee SD: Increasing trend of the incidence of
esophageal squamous cell carcinoma, but not adenocarcinoma, in
Taiwan. Cancer Causes Control. 21:269–274. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
He YT, Hou J, Chen ZF, Qiao CY, Song GH,
Meng FS, Jin HX and Chen C: Trends in incidence of esophageal and
gastric cardia cancer in high-risk areas in China. Eur J Cancer
Prev. 17:71–76. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Porta C, Paglino C and Mosca A: Targeting
PI3K/Akt/mTOR Signaling in Cancer. Front Oncol. 14:642014.
|
|
9
|
Lee JJ, Loh K and Yap YS: PI3K/Akt/mTOR
inhibitors in breast cancer. Cancer Biol Med. 12:342–354.
2015.PubMed/NCBI
|
|
10
|
Hu A, Sun M, Yan D and Chen K: Clinical
significance of mTOR and eIF4E expression in invasive
ductalcarcinoma. Tumori. 100:541–546. 2014.PubMed/NCBI
|
|
11
|
Liu NB, Zhang JH, Liu YF, Li J, Zhang ZZ,
Li JW, Liu WY, Huang C, Shen T, Gu CW, et al: High DEPTOR
expression correlates with poor prognosis in patients with
esophageal squamous cell carcinoma. Onco Targets Ther. 8:3449–3455.
2015.PubMed/NCBI
|
|
12
|
Burris HA III: Overcoming acquired
resistance to anticancer therapy: Focus on the PI3K/AKT/mTOR
pathway. Cancer Chemother Pharmacol. 71:829–842. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang M: Research progress of a Chinese
herb Celastrus on antitumor effect. J Chinese Medicine.
25:1055–1057. 2010.(In Chinese).
|
|
14
|
Li JJ, Yang J, Lu F, Qi YT, Liu YQ, Sun Y
and Wang Q: Chemical constituents from the stems of Celastrus
orbiculatus. Chin J Nat Med. 10:279–283. 2012.(In Chinese).
View Article : Google Scholar
|
|
15
|
Zan K, Chen X, Wang Q and Cao L: Chemical
constituents in stem of Celastrus orbiculatus. Chin Tradit Herbal
Drugs. 38:14552007.(In Chinese).
|
|
16
|
Qian YY, Zhang H, Hou Y, Yuan L, Li GQ,
Guo SY, Hisamits T and Liu YQ: Celastrus orbiculatus extract
inhibits tumor angiogenesis by targeting vascular endothelial
growth factor signaling pathway and shows potent antitumor activity
in hepatocarcinomas in vitro and in vivo. Chin J Integr Med.
18:752–760. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang M, Zhang X, Xiong X, Yang Z, Sun Y,
Yang Z, Hoffman RM and Liu Y: Efficacy of the Chinese traditional
medicinal herb Celastrus orbiculatus Thunb on human hepatocellular
carcinoma in an orthothopic fluorescent nude mouse model.
Anticancer Res. 32:1–1220. 2012.PubMed/NCBI
|
|
18
|
Zhang H, Qian Y, Liu Y, Li G, Cui P, Zhu
Y, Ma H, Ji X, Guo S and Tadashi H: Celastrus orbiculatus extract
induces mitochondrial-mediated apoptosis in human hepatocellular
carcinoma cells. J Tradit Chin Med. 32:621–626. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Qian YY and Liu YQ: Inhibition of
Celastrus orbiculatus extracts on VEGF expression in hepatoma cells
of mice. Chinese Herbal Med. 2:72–76. 2010.
|
|
20
|
Hui MA, Yayun Q, Hua Z, Xue J, Yaodong Z,
Pingfang C and Yanqing L: Celastrus orbiculatus extract could
inhibit human colorectal carcinoma HT-29 cells metastasis via
suppression of the mTOR signaling pathway. Life Sci J.
10:1704–1710. 2013.
|
|
21
|
Li G, Liu D, Guo S, Sunagawa M, Hisamitsu
T and Liu Y: Anti-invasive effects of Celastrus orbiculatus extract
on interleukin-1 betaand tumour necrosis factor-alpha
combination-stimulated fibroblast-likesynoviocytes. BMC Complement
Altern Med. 14:622014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu Y, Liu Y, Qian Y, Dai X, Yang L, Chen
J, Guo S and Hisamitsu T: Antimetastatic effects of Celastrus
orbiculatus on human Gastricadenocarcinoma by inhibiting
epithelial-mesenchymal transition and NF-κB/snail signaling
pathway. Integr Cancer Ther. 14:271–281. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu YD, Liu YQ, Qian YY, Zhang H, Li GQ
and Yang L: Extracts of Celastrus orbiculatus exhibit
anti-proliferative and anti-invasiveeffects on human gastric
adenocarcinoma cells. Chin J Integr Med. Nov 10–2014.(Epub ahead of
print). View Article : Google Scholar
|
|
24
|
Zhu Y, Liu Y, Qian Y, Yang L, Chen J, Guo
S and Hisamitsu T: Research on the efficacy of Celastrus
orbiculatus in suppressing TGF-β1-induced epithelial-mesenchymal
transition by inhibiting HSP27 and TNF-α-induced NF-κB/Snail
signaling pathway in human gastric adenocarcinoma. BMC Complement
Altern Med. 14:4332014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tao W, Luo X, Cui B, Liang D, Wang C, Duan
Y, Li X, Zhou S, Zhao M and Li Y: Practice of traditional Chinese
medicine for psycho-behavioral intervention improves quality of
life in cancer patients: A systematic review and meta-analysis.
Oncotarget. 6:39725–39739. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu H, Zhao X, Liu X, Xu P, Zhang K and Lin
X: Antitumor effects of traditional Chinese medicine targeting the
cellularapoptotic pathway. Drug Des Devel Ther. 9:2735–2744.
2015.PubMed/NCBI
|
|
27
|
Zhang YS, Shen Q and Li J: Traditional
Chinese medicine targeting apoptotic mechanisms for esophageal
cancer therapy. Acta Pharmacol Sin. 37:295–302. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu Z, Ding Y, Ye N, Wild C, Chen H and
Zhou J: Direct activation of bax protein for cancer therapy. Med
Res Rev. 36:313–341. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Thomas S, Quinn BA, Das SK, Dash R, Emdad
L, Dasgupta S, Wang XY, Dent P, Reed JC, Pellecchia M, et al:
Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther
Targets. 17:61–75. 2013. View Article : Google Scholar : PubMed/NCBI
|
